Netscientific Share Discussion Threads

[loafofbread] 26/5/2023 09:49

How that is a RNSNON is beyond me?

[blakieboy7] 26/5/2023 09:48

Loaf, I'm expecting fireworks when pdsb opens today

[loafofbread] 26/5/2023 09:42

3 delayed 10K buys from first thing so approx 3 to 1 on the buy side.

Very surprised at the lack of movement.

Perhaps when PDSB opens 25% up people might notice.

RNS from NSCI might help.

I had always thought $30 (approx $1B) would do it but the data is so good your $50 looks more likely later this year.

Approx £65 Million to NSCI or 4 times our market cap.

An instant gap up to £3.00+ a ahare should wake people up.

2p profit now or wait a few months. Go figure.

[blakieboy7] 26/5/2023 09:41

Well better late than never for the RNS

[wapper] 26/5/2023 09:35

On May 25, 2023, PDS Biotechnology Corporation (the “Company”;) issued a press release promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. The results will be featured in a poster presentation and in a head and neck cancer expert panel discussion at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago.

[pbesz] 26/5/2023 08:50

Hoping for a not too early buy out. But I think MRK will do the job under $50.

[loafofbread] 26/5/2023 08:26

The results posted last night were pretty staggering. They confirm 100% the mode of action for PDSB.

Keytruda is the biggest selling drug in the world doing approx $25B of sales a year.

Add PDS0101 to Keytruda and it is twice as effective and patients are living twice as long (and still going) with less side effects.

If the PDSB platform works across other cancers with Keytruda then do the maths.

MRK is one of the richest companies in the the Bio world and won't want to lose PDSB.


In measuring the efficacy of PDS0101 in combination with KEYTRUDA®, the abstract highlights the following interim data:

Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone*.
Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels*.
A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)
Confirmed and unconfirmed objective response rate was 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported at ASCO 2022 (7/17 patients). To date these responses have been confirmed in nine of the 34 patients (26.5%), including one complete response.
15/34 patients (44.1%) had stable disease.
9/34 patients (26.5%) had progressive disease.
4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.

[blakieboy7] 26/5/2023 08:08

It's the lack of NSCI RNS loaf

[loafofbread] 26/5/2023 08:08

Bonkers.

PDSB was up 30% after hours adding $60M+ to it's value.

Thats $3M to us.

We should be up a good 15%+

Bought 10k at 69/70 which in a few months time should be a gift.

[blakieboy7] 26/5/2023 07:19

Very surprised NSCI haven't issued the ODSB RNS yet however

[blakieboy7] 26/5/2023 06:54

100% this will move north today

[pbesz] 25/5/2023 23:26

PDSB will be triple digit in a year if no one takes them out.

[btgman] 25/5/2023 22:58

Very significant news from pdsb as usual uk market will probably ignore the news. PDSB is going to be worth a telephone number
AIMHO
GLA
BTG

[blakieboy7] 25/5/2023 22:11

PDSB already up over 22% after hours

[blakieboy7] 25/5/2023 22:09

PDSB news https://www.globenewswire.com/news-release/2023/05/25/2676752/37149/en/PDS-Biotech-Announces-Interim-Data-Demonstrates-12-Month-Survival-Rate-of-87-with-PDS0101-in-Combination-with-KEYTRUDA-pembrolizumab-for-Head-and-Neck-Cancer-Patients.html

[lazygun] 25/5/2023 02:04

you'd think so

l

[loafofbread] 24/5/2023 21:29

From Nov 22 fund raise.

This investment will result in the direct equity holding in Sofant by NetScientific of 1.8% at an aggregate value of GBP0.4m based on this funding round, in addition to EMVC's Capital Under Advisory representing 27.2%

[...]

Worth a lot more after todays news.

[lazygun] 24/5/2023 16:56

sofant and immarsat collaboration.

surprised no commentaary on this today:

NetScientific PLC Sofant and Inmarsat announce joint development
24/05/2023 7:00am
RNS Non-Regulatory

TIDMNSCI

NetScientific PLC

24 May 2023

Reach: 24 May 2023

NetScientific plc

("NetScientific" or the "Company")

Sofant Technologies and Inmarsat Government to develop Phased Array Antenna for Aircraft

NetScientific Plc (AIM: NSCI), investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies, reports that its portfolio company, Sofant Technologies ("Sofant"), a leading innovator in advanced antenna technologies, and Inmarsat Government ("Inmarsat"), the leading provider of secure, global, mission-critical telecommunications to the US Government, have today announced a joint development aimed at revolutionising the communication capabilities of aircraft.

Together, Sofant and Inmarsat will collaborate on a state-of-the-art phased array antenna designed to enhance connectivity, reliability, and performance in airborne operations.

The collaboration will combine their respective expertise to develop an innovative solution that addresses the Government airborne users' growing demand for efficient, low-profile communication systems.

The new phased array antenna will leverage Sofant's core technology to produce a compact, lightweight, and low-power terminal, which will enable reliable, seamless high-speed global coverage on a wider range of aircraft through Inmarsat's Global Xpress (GX) network, the world's first and only high-throughput commercial wideband network available worldwide. This includes seamless switching on the GX commercial network 's global service beams and Inmarsat's high-capacity, global military Ka-band (Mil Ka) network 's steerable beams.

David Wither, CEO, Sofant Technologies, said:

"We are thrilled to partner with Inmarsat Government on this development program. By leveraging our leading-edge antenna technology, we aim to deliver a transformative solution that will redefine communication capabilities for airborne platforms. This collaboration aligns with our vision of revolutionizing connectivity in the aerospace industry and beyond. We are confident that our joint efforts will yield exceptional results."

Steve Gizinski, President, Inmarsat Government, said :

"We are dedicated to providing cutting-edge communication solutions that empower our customers to excel in their missions. Collaborating with Sofant Technologies allows us to push the boundaries of innovation further, and together, we will develop a phased array antenna that sets new industry standards. This collaboration represents a significant step forward in meeting the Government's growing demand for secure and reliable connectivity worldwide."

Dr Ilian Iliev, CEO of NetScientific, added:

"We gained exposure to the Sofant investment through our acquisition of EMV Capital and its portfolio, and since then NetScientific has supported investments through our capital light investment approach, combining direct and advised stakes. A key feature of our deep tech investment model is to encourage portfolio companies to work closely with global OEMs as a capital efficient way of growth, and to internationalise early. Hence, we are delighted with today's announcement, which is a significant milestone for Sofant. The development collaboration between Inmarsat and Sofant underscores their commitment to driving advancements in airborne communication technology."

-Ends-

For more information, please contact:

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj [phone]
Belvedere Communications

John West / Llew Angus [phone]

Email: [e-mail]

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASEUFMDEDSEFI

(END) Dow Jones Newswires

May 24, 2023 02:00 ET (06:00 GMT)

[kingston78] 24/5/2023 15:50

MMs are manipulating the share price by widening the spread.

Anyway, short term traders and sellers of NSCI shares do not understand the potential of this company. They may make a few bucks here and there, but will miss out big time when there is a quantum leap in gigantic scale when one or more of its portfolio companies float onto the stock market, which alone will be bigger than NSCI itself.

[blakieboy7] 24/5/2023 10:46

Also PDSB could get really interesting very soon ACSCO fast approaching

[loafofbread] 24/5/2023 10:36

Impressive contract.

Looking forward to the results/explanation and revaluation.